48,018 Shares in OraSure Technologies, Inc. (NASDAQ:OSUR) Acquired by Marquette Asset Management LLC

Marquette Asset Management LLC purchased a new position in OraSure Technologies, Inc. (NASDAQ:OSUR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 48,018 shares of the medical instruments supplier’s stock, valued at approximately $205,000. Marquette Asset Management LLC owned 0.06% of OraSure Technologies as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in shares of OraSure Technologies in the first quarter worth $72,000. Tocqueville Asset Management L.P. grew its position in OraSure Technologies by 20.0% in the 1st quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock valued at $93,000 after acquiring an additional 2,512 shares during the last quarter. Mackenzie Financial Corp purchased a new position in OraSure Technologies in the 2nd quarter worth about $72,000. Tidal Investments LLC bought a new stake in shares of OraSure Technologies during the first quarter valued at approximately $116,000. Finally, Counterpoint Mutual Funds LLC purchased a new stake in shares of OraSure Technologies in the 1st quarter worth $131,000. Institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on OSUR. Evercore ISI lifted their target price on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research note on Wednesday, August 7th. StockNews.com raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 4th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, OraSure Technologies has an average rating of “Moderate Buy” and an average target price of $6.67.

OraSure Technologies Price Performance

Shares of NASDAQ:OSUR opened at $4.09 on Wednesday. OraSure Technologies, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $8.45. The stock has a market cap of $302.49 million, a price-to-earnings ratio of 13.63 and a beta of 0.05. The firm’s 50 day moving average price is $4.29 and its 200 day moving average price is $4.71.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share for the quarter. The business had revenue of $54.34 million for the quarter, compared to the consensus estimate of $53.35 million. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. On average, equities analysts anticipate that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.